Publication details

Inhibitory tyrozinkináz v léčbě CML - která dávka je ta pravá?

Title in English Tyrosine kinase inhibitors in the treatment of CML - which dose is right?
Authors

ŽÁČKOVÁ Daniela

Year of publication 2023
MU Faculty or unit

Faculty of Medicine

Citation
Description A prospective phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitor withdrawal after prior two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission The HALF clinical trial is designed as a prospective, multicenter, nonrandomized, open-label phase II study to assess the efficacy and safety of tyrosine kinase inhibitor withdrawal after a prior two-step dose reduction in patients with chronic myeloid leukemia in deep remission. The clinical evaluation of HALF could contribute to the formulation of a new disease management strategy for patients achieving sustained remission with the potential for wider benefits not only for the patients themselves, but also for the healthcare system.

You are running an old browser version. We recommend updating your browser to its latest version.

More info